Skin cancer screening has quietly become a two-track discipline: the dermatologist's eye and the algorithm's classifier, working the same lesion from different angles. The framework that still anchors the human side is the ABCDE rule — asymmetry, border irregularity, color variation, diameter over 6 mm, and evolution over time — a checklist any patient can learn before they ever book an appointment.

Medical News Today recently walked through what a modern screening appointment looks like, and the picture it draws is one of layered detection rather than replacement. The dermatologist looks first. The machine looks second, or alongside.

What does a screening appointment actually involve?

A full-body skin exam remains the core procedure. The dermatologist inspects the skin from scalp to soles, often with a dermatoscope — a handheld magnifier with polarized light that reveals structures under the skin surface invisible to the naked eye. Any suspicious lesion gets photographed, measured, or biopsied on the spot.

The ABCDE criteria guide that judgment:

• Asymmetry — one half of the mole doesn't match the other
• Border — ragged, blurred, or irregular edges
• Color — multiple shades of brown, black, red, or white in one lesion
• Diameter — larger than 6 mm, roughly the size of a pencil eraser
• Evolving — any change in size, shape, color, or symptoms such as itching or bleeding

The rule targets melanoma, the form of skin cancer most likely to spread. Takeaway in plain words: if a mole changes, that alone is reason to see a dermatologist, whatever its size.

Where does AI enter the exam room?

Computer-aided tools now analyze lesion images and flag ones that warrant a closer look. Smartphone apps let patients photograph their own moles and receive a risk assessment, and clinics increasingly use algorithm-based imaging systems during in-person exams. The technology's promise is triage: catching the lesions a tired eye might rank too low, and pushing high-risk patients toward an appointment sooner.

But the dermatologist stays in the loop. AI output is a decision aid, not a diagnosis, and regulators and clinicians alike treat it that way. A suspicious-looking lesion comes out regardless of what the software says, and a benign-looking one that has changed dramatically still earns a biopsy conversation.

Takeaway: the algorithm narrows the field; the dermatologist makes the call.

Why early detection still drives everything

Caught early, melanoma is highly treatable. Caught late, it's one of the most dangerous skin cancers. That asymmetry is the entire economic and clinical argument for screening programs, patient self-exams, and now AI-assisted triage — every tool exists to move diagnosis left on the timeline.

Dermatologists also track risk factors during screening: fair skin, a history of sunburns, family or personal history of skin cancer, immunosuppression, and a high count of atypical moles. Patients in those groups are counseled on screening frequency and self-examination, with the ABCDE checklist as their homework.

Takeaway: screening works because the payoff for finding a melanoma early is enormous, and the cost of missing one is higher.

What comes next?

The likely path is integration rather than substitution — AI image analysis embedded in routine visits, patient-owned photo tracking between appointments, and dermatologists spending their time on the judgment calls machines can't make. For now, the advice is simple: learn the ABCDEs, photograph anything that worries you, and get a professional look at anything that evolves.